CTX Blood Test Explained: What It Measures and Why It's Ordered

This page is for educational purposes only and is not medical advice; consult a licensed physician or the clinician who ordered the test about any individual result. Nothing here interprets a personal laboratory value, and no reference ranges are offered as guidance.

Two different things are abbreviated "CTX"

The letters CTX appear in two unrelated areas of laboratory medicine, which is a common source of confusion when a result or a requisition form is read out of context. In bone metabolism, CTX refers to the C-terminal telopeptide of type I collagen (often written CTX-I or β-CTX), a peptide fragment measured in blood as an index of bone resorption; reviews of calcium and bone metabolism indices described this family of collagen-derived fragments as products of the degradation of the type I collagen matrix of bone (PMID 28939209). In lipidology and neurology, CTX is the abbreviation for cerebrotendinous xanthomatosis, a rare inherited disorder of bile acid synthesis; an update review described it as a treatable lipid storage disease in which cholestanol accumulates in tissues (PMID 33630770).

Where the CTX-I analyte comes from

Type I collagen forms the bulk of the organic matrix of bone. When osteoclasts resorb bone, cross-linked telopeptide fragments from the ends of the collagen molecule enter the circulation and are eventually cleared by the kidney. Reviews of bone turnover markers described these fragments as being measured in serum and urine to give a dynamic picture of skeletal remodelling that is distinct from the static measurement of bone mineral density by densitometry (PMID 27374301). Because the signal reflects whole-body resorption activity rather than a single site, the literature has generally framed CTX as a systemic index rather than a site-specific one (PMID 28271451).

Formation versus resorption markers

Bone turnover markers are conventionally split into markers of formation, such as procollagen type I N-propeptide (PINP), bone-specific alkaline phosphatase and osteocalcin, and markers of resorption, such as CTX-I and the N-terminal telopeptide; a 2025 consensus paper from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases, the International Osteoporosis Foundation and the International Federation of Clinical Chemistry and Laboratory Medicine reaffirmed serum CTX-I and serum PINP as the reference markers for resorption and formation respectively (PMID 40152990). Reviews of biomarker utility described the two classes as complementary, since in most metabolic bone disease formation and resorption move together (PMID 28271451).

What the test measures and how

The CTX blood test is an immunoassay. Automated platforms detect the β-isomerised form of the C-terminal telopeptide octapeptide, which is why the analyte is often labelled β-CTX or β-CrossLaps on a report. The 2025 ESCEO/IOF/IFCC consensus paper addressed analytical and pre-analytical standardisation of these assays and emphasised harmonised sample handling and the use of assay-specific reference data (PMID 40152990). Reviews of bone turnover marker use in osteoporosis similarly described the need for consistent collection conditions and for the same assay to be used when serial measurements are compared (PMID 27374301).

Serum and plasma are both used depending on the platform and the laboratory's validated protocol. Urinary telopeptide assays exist as an alternative resorption measure, and reviews have discussed them alongside serum CTX while noting that the serum assay has become the preferred form for clinical use (PMID 28271451).

Why clinicians order a CTX test, as described in the literature

Published reviews and consensus documents have described several contexts in which bone resorption markers are requested. None of the following is a recommendation; it is a summary of what the cited sources reported.

• Characterising bone turnover in metabolic bone disease. Reviews described bone turnover markers as tools that reflect the current rate of remodelling, complementing densitometry, which changes slowly (PMID 27374301).
• Monitoring response to antiresorptive treatment. The 2025 consensus paper discussed the role of bone turnover markers, including serum CTX-I, in the diagnosis and management of osteoporosis, including monitoring of therapy (PMID 40152990).
• Assessing changes after treatment is stopped. A real-world prospective study in fractured post-menopausal women reported that early administration of romosozumab prevented the rebound of bone resorption associated with denosumab withdrawal (PMID 39888498).
• Research into secondary bone disease. Investigators have measured bone-related serum markers in non-osteoporotic settings; one study reported increased serum sclerostin in children after surgery for biliary atresia, illustrating how hepatobiliary disease has been studied for its skeletal effects (PMID 25659290).

Reviews have also cautioned that bone turnover markers have been examined as adjuncts rather than as stand-alone diagnostic tests, and that diagnosis of osteoporosis has continued to rest on densitometry and fracture history (PMID 28271451).

High and Low CTX Values: What Studies Report

Literature on bone turnover markers has associated higher resorption-marker concentrations with states of accelerated remodelling. Reviews described increased bone turnover in the post-menopausal state and in various metabolic bone disorders, with markers such as CTX reflecting that increased remodelling activity (PMID 27374301). Reviews of calcium and bone metabolism indices placed the collagen telopeptides among the laboratory indices used to describe disturbances of calcium and skeletal homeostasis (PMID 28939209).

At the other end, suppression of resorption markers has been described during antiresorptive therapy, and the rebound phenomenon after discontinuation of denosumab has been a specific focus: researchers in the real-world prospective study cited above reported that the rebound in bone resorption after denosumab withdrawal was prevented when romosozumab was started early in fractured post-menopausal women (PMID 39888498). Because a single value sits within a wide distribution shaped by age, sex, kidney function, recent fracture and medications, consensus guidance has emphasised interpretation against appropriate reference data rather than in isolation (PMID 40152990).

Assay and interpretation caveats

Reviews of bone turnover markers in osteoporosis described substantial pre-analytical and biological variability as the main practical limitation of these tests, and discussed standardised collection conditions as a way to reduce it (PMID 27374301). The 2025 ESCEO/IOF/IFCC consensus paper likewise addressed variability, sample handling and the comparability of results between methods as central issues for the clinical use of serum CTX-I (PMID 40152990). Points repeatedly raised in that literature include:

1. Serial results are most informative when the same assay and the same laboratory are used (PMID 40152990).
2. Marker concentrations reflect whole-skeleton remodelling, not the strength of any one site (PMID 28271451).
3. Markers have been positioned as adjuncts to, not replacements for, imaging and clinical assessment (PMID 27374301).

Any individual value, trend or flagged result is for the ordering clinician to interpret in the context of the person's history, medications and other laboratory indices.

The other CTX: cerebrotendinous xanthomatosis

When CTX refers to cerebrotendinous xanthomatosis, the laboratory approach is entirely different. An update review described the condition as an autosomal recessive disorder of bile acid synthesis caused by sterol 27-hydroxylase (CYP27A1) deficiency, leading to accumulation of cholestanol with neurological and tendon manifestations (PMID 33630770). A literature review with an accompanying case study described the diagnostic pathway as combining clinical features such as tendon xanthomas and neurological signs with biochemical and genetic confirmation (PMID 39717439).

Biochemically, plasma cholestanol is the classical analyte. Methodological work on plasma non-cholesterol sterols described chromatographic approaches for separating and quantifying these sterols, which underpin cholestanol measurement (PMID 11762775), and a review of cholestanol metabolism discussed its molecular pathology and nutritional implications (PMID 14585188). Importantly, the biochemistry is not uniform: a 2024 report described rare genetic CTX cases without cholestanol elevation but with prominent cholesterol-rich tendon xanthomas, which the authors noted as a potential pitfall when screening relies on cholestanol alone (PMID 38906752).

In short, a requisition for "CTX" in a bone clinic and a workup for "CTX" in a neurogenetics or lipid clinic involve different analytes, different methods and different clinical questions. Distinguishing the two before reading any result is the first step the literature implies.

What the CTX-I test does not do

Reviews have been consistent that resorption markers do not diagnose osteoporosis on their own, do not measure bone density, and do not identify the cause of an abnormal turnover state without additional testing (PMID 28271451). The 2025 consensus paper framed bone turnover markers as part of a broader diagnostic and management framework rather than as a standalone decision tool (PMID 40152990). Questions about whether a test is appropriate, how often it should be repeated, and what a given number means in a particular person are clinical decisions outside the scope of an educational summary.

References

• Update on the role of bone turnover markers in the diagnosis and management of osteoporosis: a consensus paper from ESCEO, IOF and IFCC (Osteoporosis International, 2025)
• Clinical usefulness of bone turnover marker concentrations in osteoporosis (Clinica Chimica Acta, 2017)
• The Utility of Biomarkers in Osteoporosis Management (Molecular Diagnosis & Therapy, 2017)
• Calcium and Bone Metabolism Indices (Advances in Clinical Chemistry, 2017)
• Early administration of romosozumab prevents rebound of bone resorption related to denosumab withdrawal in fractured post-menopausal women: a real-world prospective study (Journal of Endocrinological Investigation, 2025)
• Increased serum sclerostin in postoperative biliary atresia (Clinica Chimica Acta, 2015)
• Update on cerebrotendinous xanthomatosis (Current Opinion in Lipidology, 2021)
• Cerebrotendinous xanthomatosis: a literature review and case study (Frontiers in Cardiovascular Medicine, 2024)
• Rare genetic cerebrotendinous xanthomatosis (CTX) cases without cholestanol elevation but with prominent cholesterol-rich tendon xanthomas (Journal of Clinical Lipidology, 2024)
• Plasma non-cholesterol sterols (Journal of Chromatography A, 2001)
• Cholestanol metabolism, molecular pathology, and nutritional implications (Journal of Medicinal Food, 2003)